Incidences of dysesthesia occurred in 5.1%, 12.3%, and 12.5% of patients treated with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 0.9% with placebo, and incidences of urinary tract infections occurred in 7.5%, 8.8%, and 8.4% of patients treated with retatrutide 4 mg, 9 mg, and 12 mg, respectively, compared with 5.3% with placebo
Switching to Ozempic to stay on a GLP-1 medication is far better than stopping treatment altogether because of cost
Exendin-4 was ultimately synthesized to Exenatide, a GLP-1RA with a half-life sufficient to permit clinical use in treating type 2 diabetes, the first in a new generation of drugs that followed
Each increase should be followed by another four-week stabilization period before the next adjustment
Recently Xie et al
Detailed health assessments before beginning GLP-1 treatment Help in choosing the right medication from todays options Tracking results helps to maintain safety and steady progress